|
EXEL's Net Income Growth by Quarter and Year
Exelixis Inc 's Net Income results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| EXEL Net Income (in millions $) |
FY 2024 |
FY 2023 |
FY 2022 |
FY 2021 |
| IV Quarter |
December |
-
|
188.56
|
-61.60
|
336.06
|
| III Quarter |
September |
-
|
6.86
|
165.25
|
91.46
|
| II Quarter |
June |
518.96
|
181.56
|
159.18
|
96.09
|
| I Quarter |
March |
86.58
|
88.31
|
153.80
|
1.60
|
| FY |
|
605.54
|
465.29
|
416.63
|
525.21
|
| EXEL Net Income second quarter 2024 Y/Y Growth Comment |
Exelixis Inc reported Net Income surge of 185.83% year on year in the second quarter 2024, to $ 518.96 millions, this is lower than Exelixis Inc 's recent average Net Income surge of 238.41%.
Looking into second quarter 2024 results within Biotechnology & Pharmaceuticals industry 2 other companies have achieved higher Net Income growth. While Exelixis Inc ' s Net Income doubling of 185.83% ranks overall at the positon no. 481 in the second quarter 2024.
|
| EXEL Net Income ( Y/Y Growth %) |
2024
|
2023 |
2022 |
2021 |
| IV Quarter |
December |
- |
- |
- |
1083.73 % |
| III Quarter |
September |
- |
-95.85 % |
80.68 % |
- |
| II Quarter |
June |
185.83 % |
14.06 % |
65.66 % |
43.8 % |
| I Quarter |
March |
-1.96 % |
-42.58 % |
9512.5 % |
-96.71 % |
| FY |
|
- |
11.68 % |
-20.67 % |
369.86 % |
EXEL Net Income (Quarter on Quarter Growth %) |
2024
|
2023 |
2022 |
2021 |
| IV Quarter |
December |
- |
2648.69 % |
- |
267.44 % |
| III Quarter |
September |
- |
-96.22 % |
3.81 % |
-4.82 % |
| II Quarter |
June |
499.4 % |
105.59 % |
3.5 % |
5905.63 % |
| I Quarter |
March |
-54.08 % |
- |
-54.23 % |
-94.36 % |
| FY (Year on Year) |
|
- |
11.68 % |
-20.67 % |
369.86 % |
| Net Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 3138.13 % |
238.41 % |
-77.96 % |
| (Mar 30 2018) |
|
(Apr 02 2021) |
|
|
| Net Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 3138.13 % |
238.41 % |
-77.96 % |
| (Mar 30 2018) |
|
(Apr 02 2021) |
|
| Net Income by Quarter for the Fiscal Years 2021, 2022, 2023, 2024 |
Exelixis Inc 's Q/Q Net Income Growth
| Net Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 5902 % |
373.71 % |
-96.22 % |
| (Jul 02 2021) |
|
|
| EXEL's II. Quarter Q/Q Net Income Comment |
Exelixis Inc achieved in the II. Quarter 2024 above company average sequential Net Income doubling of 499.4%, to $ 518.96 millions, from $86.58 millions in the first quarter.
Biotechnology & Pharmaceuticals company is undergoing a remarkable growth, not only claiming better then normal growth, and also increasing rate, Diya Tambe , market consultant mentioned.
Within Biotechnology & Pharmaceuticals industry Exelixis Inc achieved highest sequential Net Income growth. While Exelixis Inc 's Net Income growth quarter on quarter, overall rank is 35. |
|
|
|
| Net Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 5902 % |
373.71 % |
-96.22 % |
| (Jul 02 2021) |
|
|
| EXEL's II. Quarter Q/Q Net Income Comment |
Exelixis Inc achieved in the II. Quarter 2024 above company average sequential Net Income doubling of 499.4%, to $ 518.96 millions, from $86.58 millions in the first quarter.
Biotechnology & Pharmaceuticals company is going from strength to strength, with claiming above regular increase, but also increasing pace.
Within Biotechnology & Pharmaceuticals industry Exelixis Inc achieved highest sequential Net Income growth. While Exelixis Inc 's Net Income growth quarter on quarter, overall rank is 35. |
|
Exelixis Inc 's 12 Months Net Income Growth Year on Year
Net Income TTM Growth |
12 Months Ending
(Jun 28 2024) |
12 Months Ending
(Mar 29 2024) |
12 Months Ending
(Dec 29 2023) |
12 Months Ending
(Sep 29 2023) |
12 Months Ending
(Jun 30 2023) |
| Cumulative Net Income 12 Months Ending |
$ 800.96 |
$ 463.56 |
$ 465.29 |
$ 215.13 |
$ 373.52 |
| Y / Y Net Income Growth (TTM) |
114.43 % |
32.02 % |
11.68 % |
-73.58 % |
-49.56 % |
| Year on Year Net Income Growth Overall
Ranking |
# 911 |
# 396 |
# 163 |
# 27 |
# 11 |
| Seqeuential Net Income Change (TTM) |
72.78 % |
-0.37 % |
116.28 % |
-42.41 % |
6.37 % |
| Seq. Net Income Growth (TTM) Overall
Ranking |
# 481 |
# 304 |
# 1441 |
# 804 |
# 300 |
| Cumulative Net Income growth
Comment |
Although Exelixis Inc 's Annual Net Income growth year on year were below company's average 238.41% , Net Income announced in the Jun 28 2024 period, show improvement in Net Income trend, to cumulative trailing twelve month growth of 114.43% year on year, from 32.02% in Mar 29 2024.
In the Healthcare sector 61 other companies have achieved higher trailing twelve month Net Income growth. While Net Income growth total ranking has deteriorated compare to previous quarter from 396 to 911. |
| Net Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
3138.13 % |
238.41 % |
-77.96 % |
|
|
|
|
|
| Net Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
3138.13 % |
238.41 % |
-77.96 % |
|
|
|
| Net Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 3 |
| Sector |
# 39 |
| S&P 500 |
# 481 |
|
| Cumulative Net Income growth
Comment |
Although Exelixis Inc 's Annual Net Income growth year on year were below company's average 238.41% , Net Income announced in the Jun 28 2024 period, show improvement in Net Income trend, to cumulative trailing twelve month growth of 114.43% year on year, from 32.02% in Mar 29 2024.
In the Healthcare sector 61 other companies have achieved higher trailing twelve month Net Income growth. While Net Income growth total ranking has deteriorated compare to previous quarter from 396 to 911. |
| Net Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
3138.13 % |
238.41 % |
-77.96 % |
|
|
|
| Net Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
3138.13 % |
238.41 % |
-77.96 % |
|
|
|
| Net Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 3 |
| Sector |
# 39 |
| S&P 500 |
# 481 |
|
266.08%